FDA issues final guidance “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Guidance for Industry.”

FDA issues final guidance “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Guidance for Industry.”
CANNANNEW REPORT

FDA issued the final guidance “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Guidance for Industry.” This guidance provides the agency’s current thinking on several topics relevant to clinical research related to the development of drugs containing cannabis and cannabis-derived compounds. FDA considered comments received on the draft guidance, issued in July 2020, as […]

Excerpt only …
READ MORE BELOW
Source : FDA issues final guidance “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Guidance for Industry.”

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.